The Danger of Smoking and E-cigarettes in Brazil

Sep.02.2022
The Danger of Smoking and E-cigarettes in Brazil
Smoking is the primary cause of lung cancer in Brazil's Mato Grosso state, with e-cigarettes becoming a popular and dangerous alternative.

In the state of Mato Grosso do Sul in Brazil, there are 15.6 cases of tracheal, bronchial, and lung cancer per 100,000 males and 7.9 cases per 100,000 females, with similar ratios. According to data from the US National Cancer Institute (INCA), these types of tumors are primarily caused by smoking.


Smoking is the second leading cause of cancer in men, with only prostate cancer having a higher incidence rate. In women, it is the third leading cause, following breast and cervical cancer.


Giovanna Figaredo, a pulmonologist who works at the St. Matthew's Hospital in Cubatão, believes that in addition to traditional smoking methods such as cigarettes, cigars, and pipes, electronic cigarettes are becoming a popular and harmful trend, especially among young people.


Many individuals believe that electronic cigarettes are "healthier," but this is a myth. We must uncover the mysterious veil of this information in order to guide people away from consumption. Electronic cigarettes are banned in Brazil because they are unsafe. Many people are even unaware of what they are inhaling, the doctor explained.


This pulmonologist has warned that smoking increases the risk of more than 20 types of cancers, in addition to the most common ones such as lung cancer, bronchial cancer, and tracheal cancer. Furthermore, smoking also increases the risk of cardiovascular diseases such as heart disease and stroke. It can lead to pulmonary diseases like chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, and decreased fertility.


In regards to e-cigarettes, the long-term damage of their use is still largely unknown due to the higher consumption rates of this generation. However, there have been cases of patients with deteriorating lung conditions such as asthma. Additionally, there is EVALI (electronic cigarette or vaping product use-associated lung injury), which is an acute lung disease associated with the use of e-cigarettes," he pointed out.


Nicotine is a disease.


Doctor Giovanna Figueiredo explained that nicotine addiction is considered a disease and is classified under the International Classification of Diseases (ICD). It can lead to physical and psychological dependency.


Experts emphasize that the first step to overcoming the difficulties of quitting smoking is willpower and determination. "I usually guide people to make changes in their daily habits, such as changing the place where they usually keep their cigarettes, delaying the first cigarette of the day as much as possible, and avoiding drinks that encourage smoking, such as coffee and alcoholic beverages. After making these changes, it is important to set a date to permanently quit tobacco use.


Doctors emphasize that certain medications can assist with quitting smoking and also help control withdrawal symptoms and anxiety. They point out that seeking professional help for guidance, planning, and medication prescriptions is crucial when needed.


Statement:


This article is compiled from third-party information and is only intended for industry-related exchange and learning.


This article does not reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for industry-related communication and research purposes.


Due to limitations in the translator's ability, translated articles may not accurately reflect the original text. It is recommended to refer to the original text for accuracy.


In regards to any domestic, Hong Kong, Macao, Taiwan, or foreign affairs, 2FIRSTS maintains complete alignment with the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU finance ministers failed to reach agreement on tobacco excise reform at the November 9, 2026 Economic and Financial Affairs Council (ECOFIN) meeting in Brussels. The Irish Council presidency's compromise secured support from 26 of the EU's 27 member states, but Malta withheld consent, preventing the Council from reaching a general approach requiring unanimity. The reform would raise minimum taxes on conventional tobacco and bring e-cigarette liquids, heated tobacco and nicotine pouches into a common EU minimum excise framework. Finland and Estonia accepted further concessions during the meeting, while the presidency proposed separating the inclusion of nicotine pouches in the framework from setting their precise minimum tax rates. Another compromise would allow ten qualifying member states until 2036 to meet certain tobacco excise requirements. Ireland intends to continue negotiations in December.
Regulations
Nov.11
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
The European Patent Office (EPO) published an appeal decision on November 17, 2026, revoking Philip Morris Products S.A.'s European nicotine pouch patent EP 3773494, covering a formulation involving free-base nicotine, ion-exchange resin and a water content of at least 15%. The decision followed an opposition and appeal brought by British American Tobacco (BAT) entity Nicoventures Trading Limited. Philip Morris withdrew its approval of the patent text during the appeal, leading the EPO to revoke the patent. A separate European patent, EP 3809884, covering the distribution of nicotine between a pouch membrane and its internal composition, had been revoked on September 24 following a challenge from another BAT entity. The patents share a 2019 priority basis, while related European divisional applications also exist.
company
Nov.18 by 2Firsts Perspectives
Special Report|RLX Technology Consolidates European Distribution Business for First Time: Q3 2026 Revenue Rises Nearly 70%, Gross Margin Falls to 23.3%
Special Report|RLX Technology Consolidates European Distribution Business for First Time: Q3 2026 Revenue Rises Nearly 70%, Gross Margin Falls to 23.3%
RLX Technology reported a 69.7% year-on-year increase in third-quarter 2026 revenue to RMB1.92 billion ($285.9 million), driven primarily by the consolidation of a newly acquired Western European distributor. International markets accounted for 86.5% of revenue. The acquisition followed RLX's RMB744 million purchase of controlling interests in UK vaping company Totally Wicked in 2025, expanding the group's directly controlled European retail and distribution operations. SEC filings also show that purchases from Shenzhen Smoore Technology Limited declined from 80% of RLX's total purchases in 2022 to 23% in 2025. Third-quarter gross margin fell to 23.3%, while GAAP operating income declined 57.7%.
Business
Nov.20